Grail, Inc. cash flow statement
In fiscal 2025, Grail, Inc.'s operations generated −$299m of cash; it spent $909,000 on capital projects, leaving free cash flow of −$300m.
Cash flow statement
| Fiscal year | 2022Jan 2023 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|
| Cash from operations | −561 | −596 | −577 | −299 | −295 |
| Depreciation and amortisation | 16 | 20 | 20 | 18 | 17 |
| Stock-based pay | 76 | 97 | 86 | 58 | 64 |
| Capital spending | 23 | 13 | 5 | 1 | 1 |
| Free cash flow | −584 | −609 | −582 | −300 | −296 |
| Free cash flow after stock pay | −660 | −706 | −668 | −358 | −360 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −105 | −93 | −95 | −77 | −63 | −64 | −87 | −81 |
| Depreciation and amortisation | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 |
| Stock-based pay | 17 | 14 | 16 | 14 | 14 | 14 | 17 | 20 |
| Capital spending | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Free cash flow | −106 | −94 | −95 | −77 | −64 | −64 | −87 | −81 |
| Free cash flow after stock pay | −123 | −107 | −111 | −92 | −78 | −78 | −104 | −101 |
Compare with peers
- Pacific Biosciences Of California, Inc. cash flow
- Quanterix Corp cash flow
- Cryoport, Inc. cash flow
- Cytek Biosciences, Inc. cash flow
- Maravai Lifesciences Holdings, Inc. cash flow
Head to head: GRAL vs PACBGRAL vs QTRXCYRX vs GRAL
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies